← All trials
NCT03641794
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2018
- Primary completion
- Mar 20, 2019
- Completion date
- Jul 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qingfeng Pharmaceutical GroupLead sponsor
- Qingfeng Pharmaceutical GroupStudy director
- Shanghai De Novo Pharmatech Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.